Karuna Therapeutics, Inc.
KRTX · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $82 | $104 | $92 | $85 |
| G&A Expenses | $47 | $32 | $27 | $24 |
| SG&A Expenses | $47 | $32 | $27 | $24 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $130 | $136 | $120 | $110 |
| Operating Income | -$130 | -$136 | -$120 | -$109 |
| % Margin | – | – | – | -16,676.8% |
| Other Income/Exp. Net | $16 | $17 | $17 | $11 |
| Pre-Tax Income | -$113 | -$119 | -$103 | -$98 |
| Tax Expense | $1 | $0 | $0 | -$11 |
| Net Income | -$114 | -$119 | -$103 | -$86 |
| % Margin | – | – | – | -13,162.4% |
| EPS | -3.01 | -3.16 | -2.75 | -2.47 |
| % Growth | 4.7% | -14.9% | -11.3% | – |
| EPS Diluted | -3.01 | -3.16 | -2.75 | -2.47 |
| Weighted Avg Shares Out | 38 | 38 | 38 | 35 |
| Weighted Avg Shares Out Dil | 38 | 38 | 38 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $17 | $17 | $11 |
| Interest Expense | $11 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$101 | -$136 | -$119 | -$109 |
| % Margin | – | – | – | -16,626.8% |